AMH, Glucose Intolerance and Metabolic Syndrome in PCOS

NCT ID: NCT02676518

Last Updated: 2016-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-30

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Association between serum anti-Mullerian hormone (AMH) level and prevalence of glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* To study the association between serum anti-Mullerian hormone (AMH) level and glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS).
* Glucose intolerance is detected by 2-hours 75 gram oral glucose tolerance test (OGTT).
* Metabolic syndrome is diagnosed by using the Harmonized criteria; the presence of any 3 of 5 following risk factors constitutes a diagnosis of metabolic syndrome.

1. Elevated waist circumference (\> 80 cm in Asian women)
2. Elevated triglycerides (\> 150 mg/dL)
3. Reduced HDL-cholesterol (\< 50 mg/dL)
4. Elevated blood pressure )systolic \> 130 and/or diastolic \> 85 mmHg)
5. Elevated fasting glucose ( \> 100 mg/dL)
* Percentage of glucose intolerance and metabolic syndrome in PCOS women as well was any differences in parameters between PCOS patients with and without glucose intolerance and metabolic syndrome will be analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

polycystic ovary syndrome women

PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study

serum

Intervention Type OTHER

Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum

Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PCOS diagnosed by Rotterdam criteria 2003

Exclusion Criteria

* Pregnancy
* Previous any hormonal uses in the last 3 months
* Previous hypoglycemic drugs or insulin-sensitising agents use in the last 3 months
* Previous chemotherapy, ovarian surgery, pelvic irradiation
* Menopause
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chulalongkorn University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Porntip Sirayapiwat

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dhirapong Charoenvidya, MD

Role: STUDY_CHAIR

Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University

Bangkok, Bangkok, Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wasamon Tunsuparp, MD

Role: CONTACT

66850658502

Porntip Sirayapiwat, MD, MSc

Role: CONTACT

66818378923

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wasamon Tunsuparp, MD

Role: primary

Porntip Sirayapiwat, MD, MSc

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

057/2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.